1. Home
  2. AGIO vs ATEN Comparison

AGIO vs ATEN Comparison

Compare AGIO & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.39

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$18.19

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
ATEN
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
AGIO
ATEN
Price
$27.39
$18.19
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$32.13
$21.50
AVG Volume (30 Days)
2.7M
687.4K
Earning Date
10-30-2025
11-04-2025
Dividend Yield
N/A
1.32%
EPS Growth
N/A
4.68
EPS
N/A
0.69
Revenue
$44,791,000.00
$284,406,000.00
Revenue This Year
$28.75
$12.37
Revenue Next Year
$139.45
$8.10
P/E Ratio
N/A
$26.20
Revenue Growth
36.26
10.27
52 Week Low
$22.24
$13.81
52 Week High
$46.00
$21.90

Technical Indicators

Market Signals
Indicator
AGIO
ATEN
Relative Strength Index (RSI) 37.05 61.28
Support Level $26.80 $17.76
Resistance Level $28.61 $18.65
Average True Range (ATR) 1.19 0.33
MACD 0.25 0.16
Stochastic Oscillator 56.00 77.47

Price Performance

Historical Comparison
AGIO
ATEN

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

Share on Social Networks: